

**Prospective, randomized, placebo-controlled, double-blind, three-arm multicenter study evaluating survival and quality of life in patients with non small-cell lung carcinoma with or without “add-on” homeopathy**

**NCT01509612**

**February 6, 2014**

# Homeopathy in cancer (HINC)

## Study protocol

Prospective, randomized, placebo-controlled, double-blind, three-arm multicenter study evaluating survival and quality of life in patients with non small-cell lung carcinoma with or without “add-on” homeopathy

Acronym: HINC

### PROJECT- OBJECTIVES & AIMS:

We want to test for

1. Survival time
2. Quality of Life (QoL)
3. Subjective well-being

of conventionally treated cancer patients, with patients who receive an “add-on” homeopathic treatment and placebo homeopathic treatment in a double blind randomized prospective non interventional three-arm clinical trial. In addition, we want to investigate homeopathy as a system versus homeopathy as a medicine.

### PROPOSER

Partner	Contact	Location	Profession / Role
Proposer Partner 1	Michael Frass	AKH KIM-1	Project leader

## 1 TABLE OF CONTENT

<b>1</b>	<b>CONTENT AND ABSTRACT .....</b>	<b>3</b>
<b>2</b>	<b>BACKGROUND.....</b>	<b>5</b>
2.1	CANCER.....	5
2.2	POTENTIAL OF HOMEOPATHY IN CANCER PATIENTS .....	5
<b>3</b>	<b>AIM HYPOTHESIS .....</b>	<b>7</b>
<b>4</b>	<b>OVERALL TRIAL DESCRIPTION.....</b>	<b>7</b>
<b>5</b>	<b>METHODOLOGY .....</b>	<b>8</b>
5.1	CLINICAL TRIAL .....	8
5.2	PARAMETER ANALYSIS.....	13
<b>6</b>	<b>INTERDISCIPLINARY PROJECT TEAM MEMBERS .....</b>	<b>14</b>
<b>7</b>	<b>PROJECT RESSOURCES.....</b>	<b>13</b>
7.1	PARTNERSHIP .....	14
7.2	RELATION TO OTHER PROJECTS .....	15
<b>8</b>	<b>POST PROJECT ACTIVITIES / RESULT EXPLOITATION.....</b>	<b>15</b>
<b>9</b>	<b>TIMETABLE OVERVIEW .....</b>	<b>15</b>
<b>10</b>	<b>WORK PLAN OVERVIEW.....</b>	<b>16</b>
<b>11</b>	<b>EFFECT ON IMPROVEMENT OF CLINICAL PRACTICE AND TREATMENT OF PATIENTS.....</b>	<b>16</b>
<b>12</b>	<b>STUDY RATIONALE .....</b>	<b>16</b>
<b>13</b>	<b>ETHICAL ASPECTS OF THE PROJECT .....</b>	<b>16</b>
<b>14</b>	<b>COMMON RULES AND REGULATIONS .....</b>	<b>16</b>
14.1	NATIONAL COOPERATION.....	17
14.2	HUMAN RESOURCES .....	17
<b>15</b>	<b>RESEARCH VENUE.....</b>	<b>17</b>

**GERMAN ABSTRACT - PROJECT SUMMARY**

Prospektive, randomisierte, placebo-kontrollierte, doppel-blinde, dreiarmlige multicenter Studie zur Evaluation des Überlebens und der Lebensqualität von PatientInnen mit nicht-kleinzelligem Lungenkarzinom mit oder ohne additive Homöopathie.

Homöopathie wird kontroversiell diskutiert. Eine frühere Studie hat gezeigt, dass eine begleitende homöopathische Behandlung Lebensqualität und subjektives Befinden im Vergleich zu nicht homöopathisch behandelten PatientInnen positiv beeinflusst (Frass M et al. Additional treatment with homeopathy in cancer patients. Third European Congress for Integrative Medicine, Berlin 2010). Das Ziel dieser prospektiven randomisierten placebo-kontrollierten, doppelblinden, drei-armigen multizentrischen Studie ist es daher, bei PatientInnen mit nicht kleinzelligen Lungenkarzinomen (NSCLC) Stadium IV sowohl die Überlebenszeit als auch die Lebensqualität und subjektives Befinden von PatientInnen mit oder ohne homöopathische Begleittherapie zu untersuchen. Eine dritte Gruppe wird ohne jegliche homöopathische Intervention hinsichtlich des Überlebens beobachtet und dient als Kontrollgruppe. Damit wird die Homöopathie als System untersucht um jegliche psychosomatische Interaktion auszuschließen. Zudem wird die „Patients´ Voice“ durch eine integrierte sozialwissenschaftliche Erhebung erforscht.

**ENGLISH ABSTRACT**

Traditionally, homeopathy is discussed controversially. A previous study showed that “add”-on homeopathic treatment of tumor patients influences life quality and subjective well-being positively as compared to patients without add-on homeopathy (Frass M et al. Additional treatment with homeopathy in cancer patients. Third European Congress for Integrative Medicine, Berlin 2010). The aim of the present prospective randomized, placebo-controlled, open-label double-blind, three-armed multicenter study is to evaluate survival as well as quality of life (QoL) and subjective well-being in add-on homeopathically treated patients with non small-cell lung carcinoma (NSCLC) IV. A third group without any homeopathic intervention is observed regarding survival and serves as a second control group. Thereby, in our project homeopathy is also investigated as a system in order to rule out any psychosomatic intervention. Furthermore, „patients´ voice“ will be investigated by an integral social scientific research.

## 2 BACKGROUND

### 2.1 CANCER

Non-small cell lung cancer (NSCLC) stage IV – Zöchbauer-Müller

#### PREVALENCE – DIAGNOSIS – TREATMENT

NSCLC comprises about 85% of all lung cancers. About 40% of patients with NSCLC are diagnosed with stage IV disease by image guided methods. These patients are treated with first-line chemotherapy.

First-line chemotherapy of advanced NSCLC consists of platinum-based doublets containing third generation anticancer drugs. Chemotherapy in addition to best supportive care improves survival with an absolute gain of approximately 10% at 1 year (NSCLC Collaborative Group JCO 2008, 26, 4617).

Median survival is about 10.1 months (Pirker R, et al; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009 2;373:1525-31) and 1-year survival rates are about 40%.

### 2.2 POTENTIAL OF HOMEOPATHY IN CANCER PATIENTS


The underlying work hypothesis of classical homeopathy is to apply a remedy which simulates symptoms as close as possible as the symptoms a sick person. It is claimed that homeopathy strengthens the body by constitutional support. In cancer patients, additional features might be of interest, such as alleviating side effects of conventional chemotherapy, radiation as well as surgical therapy; ameliorating secondary diseases; and improving life quality.

In principle, the additive homeopathic treatment of cancer patients is not different from treatment of patients suffering from various other diseases.

A recent study describes the process and outcome of a selected case series review through the NCI BCS Program. The results of the review were deemed to be sufficient to warrant NCI initiated prospective research follow-up in the form of an observational study (Banerji P, Campbell D, Banerji P. Cancer patients treated with the Banerji protocols utilizing homoeopathic medicine: A Best Case Series Program of the National Cancer Institute. USA Oncology Reports 20: 69-74, 2008). Two patients with lung carcinoma showed complete remission without conventional therapy.

Dario Spinedi and Jens Wurster have published a book describing the use of homeopathy in severe cancer cases (Jens Wurster: Homeopathic treatment and cure of cancer and metastasized carcinoma, Peter Irl Verlag, 2010).

A previous study suggests a possible positive effect of “add-on” homeopathic treatment with regard to life quality and subjective well-being in patients suffering from various tumor entities and stages (Frass M et al. Additional treatment with homeopathy in cancer patients. Third European Congress for Integrative Medicine, Berlin 2010). Three questionnaires, the EORTC QLQ-C30, the SF-36, as well as a specific new validated questionnaire were completed by the patients at the first appointment as well as at each follow-up. The questionnaires had to be completed at least three times to evaluate a possible influence of homeopathic medication. A colleague mentioned that she has the impression that cancer patients treated additively with homeopathy live longer. Therefore, we performed a thesis evaluating survival. To our surprise, patients lived much longer than expected:



The aim of the proposed study is to evaluate whether survival as well as life quality and subjective well-being might be influenced by homeopathy in patients suffering from non-small cell lung carcinoma (NSCLC) stage IV.

### **3 AIM HYPOTHESIS**

We aim to investigate the validity of our previous results (Frass M et al. Additional treatment with homeopathy in cancer patients. Third European Congress for Integrative Medicine, Berlin 2010) in a randomized prospective, placebo-controlled, double-blind, three-arm multicenter controlled evaluation of survival as well as of QoL by questionnaires in patients with advanced NSCLC. We plan to compare the treatment outcome (survival and QoL) in tumor patients, receiving verum or placebo homeopathic treatment. A third group without any homeopathic intervention is observed regarding survival and serves as non-interventional control group. Thereby, homeopathy is also investigated as a system to rule out any psychosomatic interaction.

The null hypothesis is that “add-on” homeopathic treatment does not create a benefit with regard to survival for NSCLC patients. In addition we evaluate Quality of Life (QoL).

### **4 OVERALL TRIAL DESCRIPTION**

In a collaboration with (see names of the interdisciplinary project team members under item “6” of this document)

1. ) specialists for conventional tumor treatment and
- 2.) trained homeopaths, we want to explore the possible effects of “add-on” homeopathic treatment in cancer patients.
  - we will perform a prospective, randomized, placebo-controlled, double-blind, multicenter evaluation of questionnaires to compare the three arms (with placebo and with verum add-on homeopathic treatment; patients with standard care without any homeopathic intervention)
  - The study parameters will be 1) patient survival, 2) quality of life and subjective well-being from time of diagnosis, 3) patients’ voice.
  - Considering the patient frequency at the proposer’s site we foresee project duration of about seven years: 300 patients will be recruited. An interim analysis with non-binding stopping for futility option will be performed after the observation of 140 events.

## 5 METHODOLOGY

### 5.1 CLINICAL TRIAL

#### 5.1.1 Patient recruitment


The newly diagnosed patients are recruited at the participating centers. Inclusion criteria are: Patients older than 18 years suffering from NSCLC stage IV or IIIB, IIIC diagnosed within the last 8 weeks. Exclusion criteria are: Patients not willing to sign informed consent and pregnant patients; sensitizing mutation of the EGFR gene or translocation of the ALK gene; hematological, hepatic or renal pathology; coronary heart disease; history of secondary tumor; major surgery within 4 weeks prior to study entry; active infection, and symptomatic peripheral neuropathy (National Cancer Institute's common toxicity criteria, version 2, grade  $\geq 2$ ); central nervous system metastases unless the metastases were treated and stable; active autoimmune disease; use of systemic immunosuppressive treatment; use of systemic treatment during the previous 2 years; active interstitial lung disease, or a history of pneumonitis for which glucocorticoids were prescribed; previous systemic therapy for metastatic disease or previous irradiation; use of any complementary and/or alternative therapy, including homeopathy other than the research treatment, during the trial. Following agreement to participate and signature on the informed consent form, the patient completes the three questionnaires as described below. Then, a classical homeopathic anamnesis is taken by the homeopathic physician. Following the anamnesis, a homeopathic repertorisation is performed. Finally, the physician explains the patient how to take the prescribed remedies without giving the names of the remedies to them. Then, the physician prescribes the remedies and telefaxes the prescription on a special form, or emails them to the pharmacy. At the pharmacy, the following stratification criteria are entered into a randomization program (Randomizer<sup>®</sup> Medical University Graz, Austria) for permuted blocks randomization: age of patient, sex, Karnofsky index, and center. The pharmacy now prepares the respective remedies and sends them blinded directly to the patient. This design insures the double-blind nature of the study as it creates a system where the treating physician is in no position to know which patient receives the verum or the placebo homeopathic medicine.

Patients declining to participate undergo standard care alone without homeopathic intervention/treatment (verum or placebo). This group serves as control group without homeopathy as a third arm of the study. This third arm is necessary to answer the question about the difference between medication and the homeopathic intervention itself (Brien S, Lachance L, Prescott P, McDermott C, Lewith G. Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic

remedy: a randomized controlled clinical trial. *Rheumatology (Oxford)*. 2011;50:1070-82).

Otherwise, one could hypothesize that the act of homeopathic intervention itself might have a significant effect which could be valuable to these terminal patients, yet our study design rules out such a scenario. For these non-participating patients, only survival time will be recorded, however, no questionnaires are completed.

We assume that the number of patients who refuse to be randomized but chose to undergo homeopathy is very low. Therefore, this arm is not considered any further in this study.



Sample size calculation is based on a significance level of 5% and a median survival of 10.1 months for group 1 (without homeopathic add-on), see Pirker (*Lancet*, 2009). Furthermore, 60 months recruitment period with a 24 months observational period in each patient is planned. Under these assumptions 300 patients (corresponding to an average accrual rate of 5 patients per month) give 85% power to detect a difference of 10.1 vs. 14.5 months.

Since the trial duration is quite long a two-stage design (O'Brien-Fleming type with equal information rates) with an interim analysis is planned using the above assumptions: An interim

Analysis with non-binding stopping for futility option will be performed after the observation of 140 events (which is expected to be after 22 months under the above assumptions). Early rejection of the null hypothesis at interim is tested at a two-sided significance level of 0.0052, the null hypothesis is accepted at interim (stopping for futility) if the p-value exceeds 0.5. The two-sided significance level for the second stage is 0.048. Maximum sample size is estimated to be 302 (corresponding to 279 events), expected (average) number of events is 209 under the null hypothesis and 242 under the alternative.

### **5.1.2 Questionnaires**

For the documentation of the quality of life, the QLQ-C30, the SF-36 and a subjective well-being questionnaire will be used at any visit.

### **5.1.3 Evaluation of patients' survival**

Overall survival is the most objective end-point to be used in a clinical cancer study. Patients' survival is recorded during control visits every 2 to 3 months. In addition, patients agree that one or two persons named by him/her may be contacted for study-specific follow-up clarification of the end-points.

### **5.1.4 Bringing in the patients' voices**

In order to investigate the impact of homeopathy on the quality of life and particularly to better understand the patients' health-seeking behavior and their experiences with complementary and alternative medicine (CAM) a qualitative social scientific study will be integral part of HINC. We seek to systematically research the ethical, legal, socio-political, and science theoretical dimensions of homeopathy as in the case of lung cancer (non small-cell lung carcinoma) exemplified. To our knowledge, there do not exist any qualitative studies at this point (Franzel, Schwiegershausen, Heusser, & Berger, 2013; Smithson, Paterson, Britten, Evans, & Lewith, 2010). As such our integrated social scientific study would constitute the first qualitative study concerning the attitudes towards and experiences with homeopathy with respect to the treatment of cancer in Austria.

In our integral social scientific study we follow suit the HINC study by conducting a systematic literature review and by operating expert interviews with a variety of individuals, such as researchers, medical experts, physicians, policy makers and homeopaths (including the project members). In the tradition of the "participatory turn" (Hajer & Wagenaar, 2003; Jasanoff, 2003) in the social sciences we understand patients as experts of their own. In order to reach out for them we prepare questionnaires investigating the reasons for their participation or non-

participation in an additive homeopathic study like HINC. Those questionnaires with closed/open questions will be distributed together with the study design and the informed consent form and will produce our first empirical data. Additionally we will ask the patients to voluntarily participate in semi-structured qualitative interviews in order to further investigate their different perceptions of and attitudes towards homeopathy as a whole system. Finally we will conduct focus groups with those patients with terminal malignancies that actually take part in the HINC study, including their carers and relatives. Ideally we will organize focus groups (consisting of 4-10 participants) after the 3rd or 4th homeopathic treatment bringing together trial participants and their relatives, friends and carers (recruiting will be performed within the ordinary recruitment process). Our focus groups design allows us to study in-depth the interactions between individuals, collectively shared and uncontested assumptions, and the emergence of collective meaning (Hennink, 2007; Kitzinger, 1994; Krueger, 2009; Lezaun, 2007; Smithson, 2000). We plan to conduct 5-10 focus groups at each location, which also will enable us to explore similarities and differences between societal groups and different locations in Austria.

Throughout the seven-year period of the proposed project, we plan to operate a circular approach of data collection and analysis (Glaser & Strauss, 1967). This mixed-methods approach will increase the validity of our findings and let us approach the phenomena of interest from various perspectives. For reasons of comparability and because of the large data sets, inductive coding and structured content analysis will be applied for analyzing the transcribed data (Krippendorff, 2004; Mayring, 2008). We will conduct the actual data analysis by using the computer software Atlas.ti. In a following step, we will explore the generated data in-depth drawing on interpretive approaches (Clarke, 2005; Fischer & Gottweis, 2012; Yanow, 2000). Nesting a qualitative study among the patients, their relatives and carers would be particularly valuable in trying to understand the impact that homeopathy has as a whole system on these patients with terminal malignancies. Finally we aim at increasing the project's overall deliberative character (Schicktanz, 2009) and we will analyze the broader social and political dimensions of homeopathy as medical practice.

#### Bibliography

Clarke, A. (2005). *Situational analysis: Grounded theory after the postmodern turn*. Sage Publications, Inc.

Fischer, F., & Gottweis, H. (Eds.). (2012). *The Argumentative Turn Revisited: Public Policy as Communicative Practice*.

- Franzel, B., Schwiegershausen, M., Heusser, P., & Berger, B. (2013). Individualised medicine from the perspectives of patients using complementary therapies: a meta-ethnography approach. *BMC Complementary and Alternative Medicine*, 13(1), 1–1. doi:10.1186/1472-6882-13-124
- Glaser, B. G., & Strauss, A. L. (1967). *The discovery of grounded theory: Strategies for qualitative research*. New Brunswick/London: AldineTransaction.
- Hajer, M. A., & Wagenaar, H. (2003). Introduction. In *Deliberative Policy Analysis. Understanding Governance in the Network Society* (pp. 1–30). Cambridge: Cambridge University Press.
- Hennink, M. M. (2007). International focus group research.
- Jasanoff, S. (2003). Technologies of Humility: Citizen Participation in Governing Science. *Minerva*, 41(3), 223–244. doi:10.1023/A:1025557512320
- Kitzinger, J. (1994). The methodology of Focus Groups: the importance of interaction between research participants. *Sociology of Health & Illness*, 16(1), 103–121. doi:10.1111/1467-9566.ep11347023
- Krippendorff, K. (2004). *Content Analysis*. SAGE.
- Krueger, R. A. (2009). [CITATION][C].
- Lezaun, J. (2007). A market of opinions: the political epistemology of focus groups. *The Sociological Review*, 55(Supplement s2), 130–151. doi:10.1111/j.1467-954X.2007.00733.x
- Mayring, P. (2008). *Qualitative Inhaltsanalyse*. Beltz.
- Schicktanz, S. (2009). The relevance of affected persons, the public, and deliberation for the empirical turn in medical ethics. *Ethik in Der Medizin*, 21(3), 223–234. doi:10.1007/s00481-009-0020-0
- Smithson, J. (2000). Using and analysing focus groups: limitations and possibilities. *International Journal of Social Research Methodology*, 3(2), 103–119. doi:10.1080/136455700405172
- Smithson, J., Paterson, C., Britten, N., Evans, M., & Lewith, G. (2010). Cancer patients' experiences of using complementary therapies: polarization and integration. *Journal of Health Services Research & Policy*, 15(suppl 2), 54–61. doi:10.1258/jhsrp.2009.009104
- Yanow, D. (2000). *Conducting Interpretive Policy Analysis*. Sage University Paper series on Qualitative Research Methods Series (Vol. 47). Thousand Oaks, CA: Sage.

## 5.2 PARAMETER ANALYSIS

The obtained and recorded raw data from this prospective, randomized, placebo-controlled, double-blind, multicenter 3 arms trial will be used to compare between the two randomized groups with regard to the following outcomes:

- primary outcome at 9 and 18 weeks versus base line:
  - QoL evaluated as Global Health Status
  - EORTC-QLQ-C30 (remaining dimensions)
  - SF-36
  - subjective well-being
- secondary outcome: overall survival time after 2 years observation from diagnosis
- side effects
- patients' voice
- If study support enables a study nurse, analysis of antiemetic medication will be included
- The non-randomized group without any add-on will be compared to each of the randomized groups with respect to overall survival (no other outcomes are measured for these patients).

### 5.2.1 Statistics

- Multiple Imputation of missing QoL outcomes using the joint modeling approach by Rizopoulos (Rizopoulos, D. JM: An R package for the joint modelling of longitudinal and time-to-event data. *J Statistical Software* 2010; **35**: 1–33.).
- Kaplan-Meier curves will be used to graphically display the survival comparison between the groups.
- Multi-variable Cox proportional hazards regression models will be used to compare the groups with respect to the survival outcome while controlling for the stratification criteria.
- ANCOVA (Analysis of Co-Variance) models will be used for the evaluation of Global Health Status and further dimensions of EORTC-QLQ-C30 and SF-36.
- Statistical analysis is done by intention-to-treat (ITT) since the use of homeopathy may be highly dependent on the compliance of the patients.
- $\alpha=0.05$  (two-sided), the significance levels for the two stages (interim, final stage) are given above (see 5.1.2). No further correction for multiple testing is done among the secondary and further outcome.

## 6 INTERDISCIPLINARY PROJECT TEAM MEMBERS

Partner	Person	Initials	Role
KIM-1	Michael Frass, MD	MF	Internal physician, Homeopath
KIM-1	Sabine Zöchbauer-Müller, MD	SZM	Oncologist, NSCLC
Otto-Wagner- Hospital Vienna	Otto Burghuber, MD	OB	Pulmonologist-Oncologist
Maria Treu Pharmacy	Ilse Muchitsch, PhD pharm	IM	Preparation of study substances, handling of placebo and verum
Dept Internal Medicine Hospital Lienz	Peter Lechleitner, MD	PL	Oncologist Homeopath
Dept Medicine Elisabethinenspital, Linz	Michael Schumacher, MD	MS	Oncologist
Center for Medical Statistics, Informatics, and Intelligent Systems	Andreas Gleiß, PhD	AG	Biostatistician
Department of Political Science/ University of Vienna	Paul Just, MA	PJ	Political Scientist

## 7 PROJECT RESSOURCES

### 7.1 PARTNERSHIP

The project benefits from the synergies of five specialized teams, which are coordinated by the project leader. The realization of the work packages is within the scope of each participating

partner. The equipment and facilities are available at the partner's institution. We request only the required additional man-power and project specific consumables for the study specific documentation work.

As each team is well experienced and equipped for the planned work, no particular investments in hardware or training of personnel is necessary.

## 7.2 RELATION TO OTHER PROJECTS

- The project largely benefits from work done previously.
- Each partners' project role is within the key competence of the according partner.

## 8 POST PROJECT ACTIVITIES / RESULT EXPLOITATION

We envision various ways of data exploitation

Publish the results in:

- National and international meetings and
- Peer reviewed journals
- Web publications
- Participation on "science days" to reach the interested public

## 9 TIMETABLE OVERVIEW

1 <sup>st</sup> year	2 <sup>nd</sup> year	3 <sup>rd</sup> year	4 <sup>th</sup> year	5 <sup>th</sup> year	6 <sup>th</sup> year	7 <sup>th</sup> year
Recruiting + treating patients	Treating patients	Treating patients  Statistical evaluation				

## **10 WORK PLAN OVERVIEW**

Preparatory work [informed consent sheets; case report form (CRF)]: March to April 2012

Distribution and collection of questionnaires: May 2012 – April 2018

Statistical evaluation: May 2019

## **11 EFFECT ON IMPROVEMENT OF CLINICAL PRACTICE AND TREATMENT OF PATIENTS**

If the outcome of the study reveals an improvement of survival, QoL, and subjective well-being it will have a severe impact on the future clinical practice for cancer patients in a way as homeopathy is a low-cost treatment and debits the public social security system to a minor degree.

In addition the acceptance of homeopathy in a clinical environment increases the trust and confidence of those therapists, who consider the additive treatment as a valuable asset in their own specialized branch.

Further on, a positive result of the study might invite potential investors and companies to support future research projects.

## **12 STUDY RATIONALE**

Improvement of survival, quality of life, and subjective well-being is the major endpoint of the trial.

## **13 ETHICAL ASPECTS OF THE PROJECT**

The advantage of potentiated homeopathic remedies is that the dosage does not affect the metabolism of the patient and does not cause interaction with conventional treatment of the involved cancer patients.

## **14 COMMON RULES AND REGULATIONS**

The study is conducted according to GCP regulations installed at the Medical University of Vienna. The study follows the Declaration of Helsinki.

#### **14.1 NATIONAL AND INTERNATIONAL COOPERATION**

This project is a nationally coordinated and financially approved study within Austria and Germany under the involvement of the general Hospital of Vienna in close cooperation with the other clinics.

#### **14.2 HUMAN RESOURCES**

In total thirteen doctors and scientific staff members are involved.

### **15 RESEARCH VENUE**

Research is performed at the

- General Hospital of Vienna;
- Otto Wagner Hospital, Vienna;
- the Hospital of Lienz (Tirol); and
- Elisabethinenspital, Department of Medicine, Linz, Austria

The personnel involved works in the outpatient units of the respective hospitals.